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Sleeping Beauty (SB) transposon based technology has been extensively applied in basic 
research and biotechnology for routine cell culture gene delivery and vertebrate transgenesis, 
and it is also investigated in various gene therapy applications. Cell tolerance for the 
transgene is a key factor during transgenesis and is modulated not only through the type but 
by the dose of expression. Our experimental results exemplify that transgenes regulated with 
high activity promoters can reduce the overall success of gene delivery. Observations 
connected to transposon donors regulated by different promoters have also revealed inverse 
correlation between transcription activity and the hyperactive variant SB100X excision 
efficiency. This competition between transcription and transposition was independent of the 
transgene coding sequence and did not alter the transgenic efficiency in general. However, 
promoters applied in the transgene cassette can produce different average copy numbers 
depending on the transcriptional activity of the transposon. Unlike the piggyBac (PB) 
transposon system, this phenomenon allows a fine balance of expression using the high copy 
potential SB system that adjusts the copy number of lower activity promoter driven transgenes 
to a higher expression level. All this contributes to a well-tolerated and satisfactory 
transgenesis, and would be important to consider in gene therapy applications. 
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1. Introduction
Mobility of transposons can be utilized for gene transfer in both experimental and 
therapeutic applications. Among the DNA transposon systems, the Sleeping Beauty (SB) 
transposon is a reconstructed element from fish genomes and it is one of the best-
characterized transposons in terms of activity in vertebrate cells (Kawakami et al., 2017; 
Narayanavari et al., 2017). The most active SB100X variant supports gene integration at a 
level approaching the efficiency of integrating viral vector systems (Mates et al., 2009). SB 
has a close-to-random integration profile, which contributes to its enhanced safety in 
therapeutic applications (Gogol-Doring et al., 2016; Kebriaei et al., 2017). In addition, its 
relative independence on species or cell type specific cellular factors allows its application in 
a wide range of cell types, including various stem cells. 
Efficient genomic integration of SB enables stable expression of large variety of 
transgenes as exemplified by several preclinical animal models and cell culture studies 
(Izsvak et al., 2010). It is generally accepted that the size of the transgene lowers transposition 
efficiency, although BAC clones over the size of 150 kb can be stably integrated by the SB 
system into vertebrate genomes (Rostovskaya et al., 2012; Wang et al., 2014). However, 
cellular tolerance to transgenesis can vary depending on the type and expression level of the 
transgene which might also modulate the overall efficiency or outcome of transgenesis. This 
is to say that the nature of the promoter and the transgene are not expected to influence 
transposition rates, rather their effects are assumed to be manifested by the interference with 
the cellular expression machinery and by the genomic defense activity of the particular cell 
type. Different transgenes can be tolerated differently in a cell type specific manner, so the 
expression dose is recommended to be carefully adjusted to avoid this selection effect. This is 
often achieved by the appropriate choice of the promoter, and some of our previous 
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experiments supported this idea: certain viral promoters (e.g. CMV, cytomegalovirus 
promoter) are strongly silenced in human embryonic stem cells as compared to other 
constitutive promoters (Orban et al., 2009), suggesting that lower activity promoters, 
especially those ones derived from endogenous sequences, could lead to a more stable long 
term transgene expression. 
Contrary to that, when optimizing the parameters of the SB and the piggyBac (PB) 
transposon systems, some experiments indicated that transcription activity of different 
promoters may additionally influence transposition efficiencies (Kolacsek et al., 2014). 
Follow up studies of long term cell culture experiments revealed that, particularly for the 
hyperactive SB100X transposase, transposon copy numbers are influenced by the choice of 
promoters, as if there was a balancing effect on the overall transgene expression. Since there 
was some indications that a strong promoter activity could interfere with SB transposition 
efficiency, this important aspect of transposon-based gene delivery awaited further careful 
examinations. Therefore, in this study we have experimentally tested how transgene 
expression provided by different activity promoters in the delivered transposon cassette could 
affect transposition efficiency. We have also addressed the question of which step of the 
transposition reaction is affected by the level of transcription, and what would the overall 
outcome of this interference have on the resulting transgenic cell number. 
2. Materials and methods
2.1. Plasmid constructs 
5 
SB100X transposase variant was expressed from a standard expression plasmid 
regulated by a CMV promoter (pCMV-SB100X) (Mates et al., 2009). SB transposon donor 
plasmids were created from the pT2 variant of the SB inverted repeat-direct repeats (IRDRs) 
(Geurts et al., 2003). Puromycin antibiotic resistance gene was cloned into the initial 
transposon plasmid with PCR technique; CAG, CMV, PGK, and SV40 promoters were 
cloned with standard restriction cassette replacements. For GFP expression plasmids, the 
puromycin coding sequences in these transposon donor plasmids were changed to GFP using 
restriction enzymes. For transfection control, the pCMV-EGFP (Clontech) expression plasmid 
was used. 
2.2. Cell maintenance and transfection method 
Human embryonic kidney cells (HEK-293) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, 1% l-glutamine, and 1% 
penicillin–streptomycin. 2x10
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 HEK-293 cells were seeded onto 12-well plates, and
transfected with FuGENE 6 reagent (Promega) in duplicate according to the manufacturer’s 
instructions. For colony assays, 10:1 or 1:10 donor – helper dose combinations were applied, 
e.g. 400 ng puromycin containing transposon donor plasmids were co-transfected with 40 ng 
pCMV-SB100X helper vector or vice versa. All transfections were supplemented with 400 ng 
pCMV-EGFP transfection control. Two days posttransfection cells were harvested and one 
tenth of the transfections were analyzed with Attune Acoustic Focusing Cytometer (Thermo 
Fisher Scientific) for GFP expressing cells. Transfection efficiencies were comparable within 
experiments, ranging from 72% to 84%. 
2.3. Transposition assay 
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For colony forming assay, 48 hours posttransfection 1% of the transfected cells were 
seeded onto cell culture Petri dishes and selected for 3 weeks with 1 μg/ml puromycin. 
Surviving cells were fixed with methanol and stained with 0.05% crystal violet in 25% 
methanol. Colonies were quantified with a universal hood gel imager model 75S, using 
Quantity One 4.4.0 software (Bio-Rad, Hercules, CA). Transgenic rates were calculated from 
the colony numbers, normalizing with the number of seeded cells and also for transfection 
efficiencies; transgenic rates are therefore defined as a percentage of transfected cells. 
2.4. Transposon copy number measurements 
For average copy number quantification, cells were harvested two days 
posttransfection and one tenths of the cells in parallels were selected in puromycin for 3 
weeks. Cells from parallels were pooled and genomic DNAs were isolated by the standard 
phenol-chloroform extraction method. Average copy numbers were quantified with a 
TaqMan
®
 assay specific for the IRDR-L (left transposon sequence), normalizing to the level
of the RPPH1 endogenous control gene as described previously (Kolacsek et al., 2011). 
Briefly, all samples were run in triplicate singleplex reactions, using 100 ng of gDNA 
template, in a final volume of 20 l. Real-time PCR measurements were performed on a 
StepOnePlus™ platform, and data were analyzed by the StepOne software version 2.1, 
according to the manufacturer’s instructions (Thermo Fisher Scientific). 
2.5. Expressivities of the promoters 
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HEK-293 cells were transfected as described above, except that 800ng GFP 
transposon donor plasmids were solely applied. Two days posttransfection cells were 
harvested and parallels were pooled. GFP expressing cells were separated with FACSAria 
flow cytometer according to the manufacturer’s instructions (Becton, Dickinson and 
Company) and seeded onto a 12-well-plate. Next day they were lysed with 500μl peqGOLD 
TriFast (VWR Peqlab) and total RNAs were extracted by standard protocol of the 
manufacturer. RNAs were treated with DNase I to remove plasmid DNA contamination. 
Reverse transcriptions were carried out with High-Capacity cDNA Reverse Transcription kit 
(Thermo Fischer Scientific) according to the manufacturer’s instructions, including negative 
controls without adding reverse transcriptase. For qPCR reactions, 5 μl of tenfold diluted 
cDNAs were applied in 20 μl reaction volume in triplicates. Reactions were carried out with 
TaqMan
®
 Gene Expression Master Mix (Thermo Fisher Scientific), and were run on
StepOnePlus real-time PCR system platform using standard protocol; results were analyzed 
by StepOne software version 2.1. TaqMan
®
 primers and probe for the GFP were: forward
primer, 5’-GAGCGCACCATCTTCTTCAAG; reverse primer, 5’-
TGTCGCCCTCGAACTTCAC; TaqMan
®
 labeled probe, 5’-ACGACGGCAACTACA. Final
concentrations of primers and probes were 900 nM and 250 nM, respectively. Ribosomal 
protein P0 (RPLP0, TaqMan
®
 assay Hs9999902_m1) was used as endogenous control and the
ΔΔCt method was applied for relative quantification. 
2.6. Excision activities 
To quantitate the excision efficiency of the hyperactive SB100X transposase on different 
transposon donors, HEK-293 cells were co-transfected with 400 ng of transposon donor and 
400 ng of SB100X expressing helper plasmids. Two days posttransfection cells were 
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harvested and parallels were pooled. Isolation of plasmid DNA and real-time qPCRs were 
carried out essentially as described previously (Kolacsek et al., 2014). Briefly, the Qiagen 
plasmid miniprep kit was used for DNA isolation with a modified protocol: the cell 
lysis/protein removal step solution was supplemented with 300 l of 1.2% sodium dodecyl 
sulfate solution and with 50 g of proteinase K. 10 ng of the purified DNA samples were used 
as templates in a two-round nested PCR where primers specific for the transposon donor 
plasmid backbone were used, amplifying sequences from post-excision plasmids that 
underwent DNA repair. Plasmids without excision do not yield PCR amplicons due to the 
large size of the transposon cassettes. The second round of the nested PCR is carried out on a 
StepOnePlus™ real-time PCR platform, using SYBR Green chemistry (Thermo Fisher 
Scientific). For normalization, PCR primers specific for the ampicillin sequence were used 
which is exclusively present on the transposon donor plasmid; excision efficiencies were then 
calculated by the Ct method.         
 
 
3. Results and Discussion 
 
3.1. Choice of promoters influence SB transgene copy numbers  
 
Our previous works with the most frequently and routinely applied two-component SB 
transfection system have showed that dose combinations of transposon donor and transposase 
expressing helper plasmids define different average transgene copy numbers after co-
transfection and selection of transgenic cells (Kolacsek et al., 2014). Ten to one (10:1) donor 
– helper ratio resulted in the highest average copy number, while one to ten (1:10) dose 
combination supported transgenic cell population with low average copy number and 
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comparably high transgenic efficiency when hyperactive SB100X was applied. Therefore 
these two dose combinations providing high and low copy numbers are well suitable to 
monitor the cell tolerance toward different promoters in the transgenesis. Four frequently used 
promoters were cloned into SB transgene cassettes expressing puromycin antibiotic resistance 
gene. These were the CAG composite promoter with CMV (cytomegalovirus) enhancer and 
two different chicken- and rabbit endogenous promoter elements, the CMV promoter, PGK- 
(phosphoglycerate kinase), and SV40 (simian virus 40) promoter. Evaluating the transgene 
delivery experiments in HEK-293 cells with colony assays, transgenic cell numbers were not 
considerably different between promoters when low transposon donor dose was applied 
(Figure 1A, 1:10 donor-helper ratio). It suggests that low transgene load is well tolerated 
independent of the type of the promoter regulating the transgene expression. More 
fluctuations were seen among promoters at high transposon donor dose (Figure 1A, 10:1 
donor-helper ratio), and CMV-puromycin transgene cassette resulted the lowest number of 
transgenic colonies suggesting lower tolerance of cells for CMV driven transgene expression. 
Moreover, when we compare the two dose combinations (10:1 vs. 1:10), in the case of CMV 
two fold difference is observed in transgenic efficiency, while the tolerance of the other types 
of promoters did not seem to depend on transposon load (Figure 1A). 
We also examined the average copy numbers of these selected transgenic cell 
populations which revealed unexpected differences between the examined promoters (Figure 
1B). Copy numbers produced by the high activity CAG and CMV promoter driven 
transposons were significantly lower at both dose combinations than in the cases of PGK and 
SV40 promoters. Next we have verified the expression activity of these promoters by 
measuring transcription with qRT-PCR. Using GFP as the transgene with different promoters, 
cells transfected with the SB constructs were sorted for GFP expressing cells by FACS two 
days following transfection, and then GFP mRNA levels were measured in those cells. CAG 
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and CMV promoters showed much higher transcription activities compared to PGK and SV40 
(Figure 2). 
 
3.2. Promoter activity influences SB excision rate 
 
At this point one could expect that differences in copy numbers of selected cells 
merely represent lower tolerance of higher transgene expression levels. This might be true in 
the case of CAG and CMV promoter. However, the much lower activity PGK and SV40 
promoters also showed at least two fold difference in copy numbers at both dose 
combinations, and expression levels produced by them differentiated to a similar extent 
(Figure 1B and Figure 2). This raises the possibility that transposase function can be directly 
influenced by the expression activity of a particular promoter in the transposon. Cell tolerance 
level for an exogenous protein expression is difficult to determine, but definitely detectable 
over a longer period of time. Immediate transposase activity in co-transfected cells is certainly 
not dependent on cell tolerance that develops later during delivery and selection of transgenic 
cells. Transposase activity is often characterized by measuring the transposon excision 
product left behind after excision and reparation of double stranded breaks on the donor 
plasmid (Mates et al., 2009; Yusa et al., 2011; Claeys Bouuaert et al., 2013; Kolacsek et al., 
2014). Quantification of excised and re-circularized donor plasmids by real-time PCR proved 
the transcription dependence of transposase activity (Figure 3). Transfecting the two 
component SB100X transposon system into HEK-293 cells, the amount of excision products 
inversely correlated with the transcription activity of promoters applied in the transposon 
cassette (compare Figure 2 and 3). Transposase activity correlates more obviously with the 
resulting copy number (Figure 3 and Figure 1B). This phenomenon was independent of the 
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type of the transgene, as both puromycin and GFP expressing transposon showed similar 
excision tendency between the examined promoters (Figure 3). 
These promoters are intended to express the transgene from a genomic locus after 
delivery; however, they also constantly regulate transcription frequency ectopically from the 
plasmid before chromosomal integration. We can draw the conclusion that this episomal 
expression could limit transposition efficiency. This idea is supported by earlier observations 
when donor plasmids methylated in vitro allows more efficient delivery in mice transgenesis, 
and the transgene will be released from repression thereafter during epigenetic 
reprogramming of embryonic stem cells (Carlson et al., 2011).  
Our experimental data led to the assumption that continuous presence of the 
transcriptional machinery owing to higher activity promoters may develop steric hindrance for 
transposition of an actively transcribed DNA substrate. We expected this competition between 
transcription and transposition to be a ubiquitous function of DNA transposons. However, in 
the case of similarly widely used piggyBac (PB) transposon system, representing a different 
superfamily of DNA transposases, we could not reproduce this phenomenon (data not shown), 
suggesting that PB transposition may also be sensitive to other factors binding to different 
promoters. Nevertheless we may conclude that both transposon systems are similarly efficient 
in establishing transgenic cells independently of promoter sequence, but SB tends to make 
different copy numbers depending on the transcription activity of the transgene and on the 
transposon donor load in delivery (Figure 1B). In connection with the latter aspect of 
SB100X, promoters with extremely high activity (like the viral-derived CMV promoter) are 
not recommended to be applied in high transposon donor dose because the expected high 
copy numbers can reduce transgenic cell number owing to bad tolerance for high level of 
transgene expression (Figure 1A). Furthermore, a remarkable selective disadvantage appears 
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for CMV driven highly expressing transgenic cells when the population is not under selective 
pressure (unpublished data). 
Competition between transcription and SB transposition allows balancing the overall 
expression level of transgene, as lower activity promoters can in fact produce higher 
transgene expression owing to higher copy number; nevertheless, this also depends on the 
dose of transposon donor and is also balanced by the tolerability of the protein. While PB 
generally produce much lower copy numbers (Grabundzija et al., 2010; Kolacsek et al., 
2014), the high copy “potential” of SB gives the opportunity for fine adjustment of copy 
number in delivery of transgene, and in addition, it makes SB quite suitable for multiple gene 
delivery (Kacherovsky et al., 2015). Based on our studies, for increased efficiency of multiple 
transgene delivery applications, using lower activity promoters is worth to consider. 
3.3. Conclusions 
Using several widely used eukaryotic promoters in SB transposon cassettes, we 
concluded that the transcription activity of the promoters applied in the transposon cassette 
interfere with SB100X transposition, and this interference is manifested at the excision step of 
transposition. The competition between transcription and transposition elevates the transgene 
copy numbers of lower activity promoters during transgenesis and as a result, the overall 
transgene expression level will be higher from weaker promoters. This “fine-tuning” of the 
gene expression produces similar expression levels from lower copy number of strong 
promoter-driven transgenes that would otherwise be less tolerated for the cells. Based on 
these new observations, we could provide an “updated user guide” for SB transposon delivery 
applications, in order to achieve the most optimal long term transgene expression levels. As a 
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first issue, transfection efficiency should be taken into considerations: at low efficiency rate 
(e.g. for hard-to-transfect cell lines), high transposon donor dose will result in sufficient 
number of transgenic cells, and can produce low average transgene copies per cell. On the 
other hand, in cases of higher transfection efficiency, the application of strong promoters (like 
CMV), especially at high donor doses, can be unfavorable due to the potential of the 
transgene silencing, as well as to the bad tolerance of cells towards highly expressing copies, 
reducing transgenic efficiency. In such cases, promoters with moderate or low transcription 
activity (typically from endogenous promoters) can be beneficial, as they are mobilized more 
effectively due to the less interference with transposition, and the level of expression can be 
optimal with higher number of integrated transgene copies. When transgene expression level 
needs more adjustments, transposon donor dosage can be used to further manipulate the 
resulting copy number. At high transfection rates, increasing the dose of transposase might 
help in increasing transposition efficiency, however, although not observed in our 
experiments, this could have an adverse effect due to the overproduction inhibition 
phenomenon (Bire et al., 2013). 
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Figure 1. Transgenic efficiencies of SB100X in HEK-293 cells depending on promoters 
of the transgene, as well as on transposon / transposase dose combinations. 
Comparison of four frequently used promoters in puromycin resistance gene containing 
transposon deliveries, using high and low transposon doses. (A) The structure of the used 
expression cassettes differ only by the indicated promoter sequences. (B-C) Transgenic rates 
determined by colony assays, and photos of CMV driven transgene colonies (two parallels 
shown for each dose). Error bars represent standard deviations of parallel transfections. For 
statistical analysis, two-sided Student’s t-tests were applied, **: p<0.01. (D) Average copy 
number quantification of the same deliveries by qPCR specific for the SB transposon IRDR-L 
sequence. Error bars represent 95% confidence intervals of parallel measurements. 
 
Figure 2. Comparison of promoter activities in HEK-293 cells by qRT-PCR. 
Four different promoters driven GFP containing SB transposon donor plasmids were 
transfected and sorted by FACS two days following transfection. Messenger RNA levels were 
measured by qPCR assay specific for GFP. No RT controls were performed in each case, and 
no amplifications were detected for either the endogenous control (P0) or GFP. Error bars 
represent 95% confidence intervals of parallel measurements. Two-sided Student’s t-tests 
were performed for statistical analysis, **: p<0.01, ***: p<0.001. 
 
Figure 3. Excision activities of SB100X in HEK-293 cells depending on promoters of the 
transgene. 
Comparison of four different promoters driven transposon donor excision with relative 
quantification by qPCR. Error bars represent 95% confidence intervals of parallel 
18 
measurements. For statistical analysis, two-sided Student’s t-tests were applied; **: p<0.01, 
***: p<0.001. 
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